Professor Stephen Mulligan

Adjunct Professor

G08 - Biochemistry and Microbiology Building
The University of Sydney


Research interests

Chronic Lymphocytic Leukaemia (CLL)

Keywords

Leukaemia; Proteomics; Haematology; Haematological malignancy; Immunology

Selected grants

2012

  • Next generation sequencing of TP53, ATM and a panel of novel target genes in an elderly clinical trial CLL cohort - correlation with cytogenetics, FISH and clinical outcomes; Badoux , Badoux X, Mulligan S, Ward C; CLL (Chronic Lymphocytic Leukemia) Global Research Foundation/Research Support.

2011

  • Patterns of differentially abundant proteins on progressive chronic lymphocytic leukaemias; Christopherson R, Mulligan S; Leukaemia Foundation of Australia/Grants in Aid.

2008

  • Proteomic responses of B-lymphoproliferative disorders to fludarabine; Christopherson R, Mulligan S; Leukaemia Foundation of Australia/Grants in Aid.

2006

  • Global phenotype profiling of chronic lymphocytic leukemia; Mulligan S, Christopherson R; CLL (Chronic Lymphocytic Leukemia) Global Research Foundation/Project Grant.

Selected publications

Download citations: PDF RTF Endnote

Journals

  • Hafner, J., Kumar, K., Mulligan, S., Ng, K. (2014). Multifocal central nervous system demyelination and Lhermitte's phenomenon secondary to combination chemotherapy for chronic lymphocytic leukaemia. Journal of the Neurological Sciences, 338(1-2), 218-219. [More Information]
  • Che, Y., Best, G., Zhong, L., Kaufman (nee Alexander), K., Mactier, S., Raftery, M., Graves, L., Mulligan, S., Christopherson, R. (2013). Hsp90 Inhibitor SNX-7081 Dysregulates Proteins Involved with DNA Repair and Replication and the Cell Cycle in Human Chronic Lymphocytic Leukemia (CLL) Cells. Journal of Proteome Research, 12(4), 1710-1722. [More Information]
  • Freeman, J., Crassini, K., Best, G., Forsyth, C., MacKinlay, N., Han, P., Stevenson, W., Mulligan, S. (2013). Immunoglobulin G subclass deficiency and infection risk in 150 patients with chronic lymphocytic leukemia. Leukemia and Lymphoma, 54(1), 99-104. [More Information]
  • Huang, P., Kohnke, P., Belov, L., Best, G., Mulligan, S., Christopherson, R. (2013). Profiles of surface mosaics on chronic lymphocytic leukemias distinguish stable and progressive subtypes. Journal of Pharmacy and Pharmaceutical Sciences, 16(2), 231-237. [More Information]
  • Best, O., Crassini, K., Freeman, J., Mulligan, S. (2013). The clinical significance of hypogammaglobulinaemia and serum immunoglobulin G subclass deficiency in patients with chronic lymphocytic leukaemia (CLL). Scandinavian Journal Of Infectious Diseases, 45(9), 729-729. [More Information]
  • Almazi, J., Mactier, S., Best, G., Crossett, B., Mulligan, S., Christopherson, R. (2012). Fludarabine nucleoside induces accumulations of p53, p63 and p73 in the nuclei of human B-lymphoid cell lines, with cytosolic and mitochondrial increases in p53. Proteomics - Clinical Applications, 6(5-6), 279-290. [More Information]
  • Mulligan, S. (2012). Monoclonal B-lymphocytosis: reflections and definitions. Leukemia and Lymphoma, 53(9), 1647-1650. [More Information]
  • Huang, P., Best, G., Belov, L., Mulligan, S., Christopherson, R. (2012). Surface profiles for subclassification of chronic lymphocytic leukemia. Leukemia and Lymphoma, 53(6), 1046-1056. [More Information]
  • Best, G., Che, Y., Singh, N., Forsyth, C., Christopherson, R., Mulligan, S. (2012). The Hsp90 inhibitor SNX-7081 synergizes with and restores sensitivity to fludarabine in chronic lymphocytic leukemia cells with lesions in the TP53 pathway: a potential treatment strategy for fludarabine refractory disease. Leukemia and Lymphoma, 53(7), 1367-1375. [More Information]
  • Henrich, S., Mactier, S., Best, G., Mulligan, S., Crossett, B., Christopherson, R. (2011). Fludarabine Nucleoside Modulates Nuclear "Survival and Death" Proteins in Resistant Chronic Lymphocytic Leukemia Cells. Nucleosides, Nucleotides and Nucleic Acids: An International Journal for Rapid Communication, 30(12), 1181-1189. [More Information]
  • Cassano, C., Mactier, S., Mulligan, S., Belov, L., Huang, P., Christopherson, R. (2010). Cladribine and Fludarabine Nucleoside Change the Levels of CD Antigens on B-Lymphoproliferative Disorders. International Journal of Proteomics, 2010 (Article ID 964251), 964251-1-964251-9. [More Information]
  • Kohnke, P., Mulligan, S., Christopherson, R. (2009). Membrane proteomics for leukemia classification and drug target identification. Current Opinion in Molecular Therapeutics, 11(6), 603-610. [More Information]
  • Barber, N., Gez, S., Belov, L., Mulligan, S., Woolfson, A., Christopherson, R. (2009). Profiling CD antigens on leukaemias with an antibody microarray. FEBS Letters, 583(11), 1785-1791. [More Information]
  • Henrich, S., Mactier, S., Crossett, B., Mulligan, S., Christopherson, R. (2008). Fludarabine induces differential expression of proteins in human leukemia and lymphoma cells. Nucleosides, Nucleotides and Nucleic Acids: An International Journal for Rapid Communication, 27, 634-640. [More Information]
  • Mulligan, S. (2007). Chronic lymphocytic leukaemia resistant to both fludarabine and alemtuzumab - Double jeopardy. Leukemia and lymphoma, 48(10), 1885-1887. [More Information]
  • Belov, L., Mulligan, S., Barber, N., Woolfson, A., Scott, M., Stoner, K., Chrisp, J., Sewell, W., Bradstock, K., Bendall, L., Sartor, M., Young, G., Wiley, J., Christopherson, R., et al (2006). Analysis of human leukaemias and lymphomas using extensive immunophenotypes from an antibody microarray. British Journal of Haematology, 135(2), 184-97. [More Information]
  • Christopherson, R., Stoner, K., Barber, N., Belov, L., Woolfson, A., Scott, M., Bendall, L., Mulligan, S. (2006). Classification of AML using a monoclonal antibody microarray. Methods in molecular medicine, 125, 241-251. [More Information]
  • Belov, L., Huang, P., Chrisp, J., Mulligan, S., Christopherson, R. (2005). Screening microarrays of novel monoclonal antibodies for binding to T-, B- and myeloid leukaemia cells. Journal of Immunological Methods, 305(1), 10-19. [More Information]
  • Wilson, P., Mulligan, S., Christopherson, R. (2004). Metabolic Response Patterns Of Nucleotides In B-Cell Chronic Lymphocytic Leukaemias To Cladribine, Fludarabine And Deoxycoformycin. Leukemia Research: clinical and laboratory studies, 28(7), 725-731.
  • Belov, L., Huang, P., Barber, N., Mulligan, S., Christopherson, R. (2003). Identification of repertoires of surface antigens on leukemias using an antibody mircroarray. Proteomics, 3(11), 2147-2154. [More Information]

2014

  • Hafner, J., Kumar, K., Mulligan, S., Ng, K. (2014). Multifocal central nervous system demyelination and Lhermitte's phenomenon secondary to combination chemotherapy for chronic lymphocytic leukaemia. Journal of the Neurological Sciences, 338(1-2), 218-219. [More Information]

2013

  • Che, Y., Best, G., Zhong, L., Kaufman (nee Alexander), K., Mactier, S., Raftery, M., Graves, L., Mulligan, S., Christopherson, R. (2013). Hsp90 Inhibitor SNX-7081 Dysregulates Proteins Involved with DNA Repair and Replication and the Cell Cycle in Human Chronic Lymphocytic Leukemia (CLL) Cells. Journal of Proteome Research, 12(4), 1710-1722. [More Information]
  • Freeman, J., Crassini, K., Best, G., Forsyth, C., MacKinlay, N., Han, P., Stevenson, W., Mulligan, S. (2013). Immunoglobulin G subclass deficiency and infection risk in 150 patients with chronic lymphocytic leukemia. Leukemia and Lymphoma, 54(1), 99-104. [More Information]
  • Huang, P., Kohnke, P., Belov, L., Best, G., Mulligan, S., Christopherson, R. (2013). Profiles of surface mosaics on chronic lymphocytic leukemias distinguish stable and progressive subtypes. Journal of Pharmacy and Pharmaceutical Sciences, 16(2), 231-237. [More Information]
  • Best, O., Crassini, K., Freeman, J., Mulligan, S. (2013). The clinical significance of hypogammaglobulinaemia and serum immunoglobulin G subclass deficiency in patients with chronic lymphocytic leukaemia (CLL). Scandinavian Journal Of Infectious Diseases, 45(9), 729-729. [More Information]

2012

  • Almazi, J., Mactier, S., Best, G., Crossett, B., Mulligan, S., Christopherson, R. (2012). Fludarabine nucleoside induces accumulations of p53, p63 and p73 in the nuclei of human B-lymphoid cell lines, with cytosolic and mitochondrial increases in p53. Proteomics - Clinical Applications, 6(5-6), 279-290. [More Information]
  • Mulligan, S. (2012). Monoclonal B-lymphocytosis: reflections and definitions. Leukemia and Lymphoma, 53(9), 1647-1650. [More Information]
  • Huang, P., Best, G., Belov, L., Mulligan, S., Christopherson, R. (2012). Surface profiles for subclassification of chronic lymphocytic leukemia. Leukemia and Lymphoma, 53(6), 1046-1056. [More Information]
  • Best, G., Che, Y., Singh, N., Forsyth, C., Christopherson, R., Mulligan, S. (2012). The Hsp90 inhibitor SNX-7081 synergizes with and restores sensitivity to fludarabine in chronic lymphocytic leukemia cells with lesions in the TP53 pathway: a potential treatment strategy for fludarabine refractory disease. Leukemia and Lymphoma, 53(7), 1367-1375. [More Information]

2011

  • Henrich, S., Mactier, S., Best, G., Mulligan, S., Crossett, B., Christopherson, R. (2011). Fludarabine Nucleoside Modulates Nuclear "Survival and Death" Proteins in Resistant Chronic Lymphocytic Leukemia Cells. Nucleosides, Nucleotides and Nucleic Acids: An International Journal for Rapid Communication, 30(12), 1181-1189. [More Information]

2010

  • Cassano, C., Mactier, S., Mulligan, S., Belov, L., Huang, P., Christopherson, R. (2010). Cladribine and Fludarabine Nucleoside Change the Levels of CD Antigens on B-Lymphoproliferative Disorders. International Journal of Proteomics, 2010 (Article ID 964251), 964251-1-964251-9. [More Information]

2009

  • Kohnke, P., Mulligan, S., Christopherson, R. (2009). Membrane proteomics for leukemia classification and drug target identification. Current Opinion in Molecular Therapeutics, 11(6), 603-610. [More Information]
  • Barber, N., Gez, S., Belov, L., Mulligan, S., Woolfson, A., Christopherson, R. (2009). Profiling CD antigens on leukaemias with an antibody microarray. FEBS Letters, 583(11), 1785-1791. [More Information]

2008

  • Henrich, S., Mactier, S., Crossett, B., Mulligan, S., Christopherson, R. (2008). Fludarabine induces differential expression of proteins in human leukemia and lymphoma cells. Nucleosides, Nucleotides and Nucleic Acids: An International Journal for Rapid Communication, 27, 634-640. [More Information]

2007

  • Mulligan, S. (2007). Chronic lymphocytic leukaemia resistant to both fludarabine and alemtuzumab - Double jeopardy. Leukemia and lymphoma, 48(10), 1885-1887. [More Information]

2006

  • Belov, L., Mulligan, S., Barber, N., Woolfson, A., Scott, M., Stoner, K., Chrisp, J., Sewell, W., Bradstock, K., Bendall, L., Sartor, M., Young, G., Wiley, J., Christopherson, R., et al (2006). Analysis of human leukaemias and lymphomas using extensive immunophenotypes from an antibody microarray. British Journal of Haematology, 135(2), 184-97. [More Information]
  • Christopherson, R., Stoner, K., Barber, N., Belov, L., Woolfson, A., Scott, M., Bendall, L., Mulligan, S. (2006). Classification of AML using a monoclonal antibody microarray. Methods in molecular medicine, 125, 241-251. [More Information]

2005

  • Belov, L., Huang, P., Chrisp, J., Mulligan, S., Christopherson, R. (2005). Screening microarrays of novel monoclonal antibodies for binding to T-, B- and myeloid leukaemia cells. Journal of Immunological Methods, 305(1), 10-19. [More Information]

2004

  • Wilson, P., Mulligan, S., Christopherson, R. (2004). Metabolic Response Patterns Of Nucleotides In B-Cell Chronic Lymphocytic Leukaemias To Cladribine, Fludarabine And Deoxycoformycin. Leukemia Research: clinical and laboratory studies, 28(7), 725-731.

2003

  • Belov, L., Huang, P., Barber, N., Mulligan, S., Christopherson, R. (2003). Identification of repertoires of surface antigens on leukemias using an antibody mircroarray. Proteomics, 3(11), 2147-2154. [More Information]

To update your profile click here. For support on your academic profile contact .